

**UCB, Inc Medical Educational Grants  
Medical Affairs  
Request for Proposal (RFP)**

***UCB.MG01.May2022***

<b>Background:</b>	<p>UCB, Inc., is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with rare diseases like Myasthenia Gravis (MG)</p> <p>MG is a rare, chronic, autoimmune, neuromuscular disorder caused by pathogenic IgG autoantibodies directed towards proteins concentrated at the neuromuscular junction.</p> <p>MG has no cure. A heterogeneous disease – symptoms can vary day by day and even hour by hour, and it can “strike at any time”</p>
<b>Key Identified Gaps:</b>	<p>Diagnosis:</p> <ul style="list-style-type: none"> <li>• The initial symptom patients experience varies in breadth and severity. This can often lead them to downplay their symptom and develop coping mechanisms instead of seeing a healthcare professional. Patients can go for months coping with the symptoms before seeking medical advice. <ul style="list-style-type: none"> <li>a. Due to the unpredictable nature of MG symptoms, misdiagnosis occurs in some patients</li> </ul> </li> </ul> <p>Treatment:</p> <ul style="list-style-type: none"> <li>• Patients cycle through periods of stability with relative control of symptoms and exacerbations that can sometimes extend to crisis.</li> <li>• Patients are not optimally controlled, even those who are perceived to be “controlled” on current treatment. Patients utilize coping skills (i.e., rest) to address the daily fluctuations and even exacerbations of their disease..</li> </ul> <p>Patient Communication:</p> <ul style="list-style-type: none"> <li>• Patients discover more about their Myasthenia by connecting with their patient advocacy groups</li> <li>• Challenge to provide reliable information consistent with a patient's health literacy to individuals who are not part of a patient advocacy group</li> </ul>
<b>Specific Interest of this RFP:</b>	<ul style="list-style-type: none"> <li>• Refractory MG – clinical profile, comorbid conditions and respond to current therapies (management)</li> <li>• MG-ADL –Use in clinical practice and clinical interpretation.</li> </ul>
<b>Eligibility Criteria:</b>	<p>The program should target the US geographic region. The education must be accredited and abide by ACCME standards.</p> <p>If accepted, the provider must attest to the terms, conditions and purposes of an educational grant as described in the electronic UCB letter of agreement. See the FAQ document in the Grants section at <a href="https://www.ucb.com/our-company/funding/usa">https://www.ucb.com/our-company/funding/usa</a> for the UCB letter of agreement content.</p>
<b>Clinical Area:</b>	Myasthenia Gravis
<b>Target Audience:</b>	-Neurologists, primary care physicians (PCPs), and clinicians involved in the care of patients with Myasthenia Gravis (Internal medicine and PCP)
<b>Outcomes:</b>	Participation (use metrics), satisfaction (CME – Eval results and feedback on Information presented) Knowledge and competence (Posttest results etc )

<b>Expected Budget Range of Applications:</b>	\$150,000 (USD)
<b>Key Dates:</b>	<p><b>RFP release date:</b> 8/15/22</p> <p><b>Proposal Deadline:</b> 9/19/2022 (deadline date for submissions) Please note the deadline is midnight Eastern Time</p> <p>Review of Proposals by External Review Panel: N/A</p> <p><b>Anticipated Proposal Notification Date:</b> 9/30/2022 (date UCB expects to notify applicant of decision)</p> <p><b>Period of Performance:</b> Start: 12/1/2022 – 6/1/2023 (anticipated start and finish date of the program)</p> <p>Please note an interim progress report will be requested depending upon timelines of the program.</p>
<b>Submission Instructions:</b>	<p>Submit applications online through the UCB eRequest-FMCP system (<a href="https://erequest.ucb.com">https://erequest.ucb.com</a>). Applicants must register for the UCB eRequest system if you are not a current registrant.</p> <p><b>**Please include <i>UCB.MG01.May2022</i> within the Request Title (Ex. UCB.MG01.May2022 – Request Title)**</b></p> <p>Select <b>Neurology</b> as the Therapeutic Area and <b>Myasthenia Gravis</b> as the Indication(s).</p> <p>Complete all required sections of the online application and submit the proposal.</p> <p>Approvals and denials will be communicated to the applicant via the eRequest system by email by the dates provided above.</p>
<b>Application Section Requirements:</b>	<ul style="list-style-type: none"> <li>• Learning objectives</li> <li>• Needs assessment with classification of identified gaps into knowledge, skills, attitudes optionally performance according to the Moore levels of outcomes based planning</li> <li>• Intended outcome level to be achieved according to the Moore Scale</li> <li>• Activity type and delivery format following instructional design principles</li> <li>• Audience type</li> <li>• Number of expected participants</li> <li>• Itemized budget (template provided on application)</li> </ul> <p><b>Document uploads for inclusion:</b></p> <ol style="list-style-type: none"> <li>1. A formal dated Letter of Request for the funding (including activity title, activity start and end date, total amount requested, total program budget amount)</li> <li>2. A comprehensive learning needs assessment plan</li> <li>3. Detailed program plan/agenda</li> <li>4. Accreditation certificate(s)</li> <li>5. W-9 for payee organization</li> <li>6. Outcomes measures plan</li> </ol>
<b>Questions:</b>	Please direct any questions that you may have to the UCB Grants Office at <a href="mailto:grants@ucb.com">grants@ucb.com</a>